Skip to main content

Manhard Kimberly

In the past year, 2 open-market sale filings worth $279.0K and no purchases.

Current role at each company

Open-market trades in the past year

Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.

Bought
–
0 filings
Sold
$279.0K
2 filings
Net
−$279.0K
Bought minus sold
Companies
1
With open-market trades

Trades

Every Form 4 that lists Manhard Kimberly as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.

INBX Inhibrx Biosciences, Inc.

Director3 trades

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Aug 30, 2024 (view filing)Aug 282 daysManhard KimberlyDirectorPPurchase+10.0K$13.98+$139.8KNew position10.0K after
Sep 10, 2026 (view filing)7:06 PM ETSep 8-92 daysManhard KimberlyDirectorSSale−1.00K$115.47−$115.5K−10.0%9.00K after2 lots
Sep 15, 2026 (view filing)5:52 PM ETSep 11-154 daysManhard KimberlyDirectorSSale−1.50K$109.03−$163.5K−16.7%7.50K after3 lots

HRTX Heron Therapeutics, Inc.

EVP, Drug Development1 trade

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
May 4, 2022 (view filing)May 31 dayManhard KimberlyEVP, Drug DevelopmentSSale−1.50K$4.76−$7.16K−12.2%10.9K after